GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » EV-to-EBIT

Telix Pharmaceuticals (Telix Pharmaceuticals) EV-to-EBIT : 305.81 (As of May. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Telix Pharmaceuticals's Enterprise Value is $3,317.1 Mil. Telix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10.8 Mil. Therefore, Telix Pharmaceuticals's EV-to-EBIT for today is 305.81.

The historical rank and industry rank for Telix Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

TLPPF' s EV-to-EBIT Range Over the Past 10 Years
Min: -42.23   Med: -19.99   Max: 309
Current: 309

During the past 9 years, the highest EV-to-EBIT of Telix Pharmaceuticals was 309.00. The lowest was -42.23. And the median was -19.99.

TLPPF's EV-to-EBIT is ranked worse than
97.92% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs TLPPF: 309.00

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Telix Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $2,154.8 Mil. Telix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10.8 Mil. Telix Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.50%.


Telix Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Telix Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals EV-to-EBIT Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -12.19 -21.05 -29.10 -23.79 194.62

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.10 - -23.79 - 194.62

Competitive Comparison of Telix Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Telix Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's EV-to-EBIT falls into.



Telix Pharmaceuticals EV-to-EBIT Calculation

Telix Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3317.081/10.847
=305.81

Telix Pharmaceuticals's current Enterprise Value is $3,317.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (OTCPK:TLPPF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Telix Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=10.847/2154.812125
=0.50 %

Telix Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $2,154.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.